64 related articles for article (PubMed ID: 12840798)
1. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).
Hidalgo M; Bloedow D
Semin Oncol; 2003 Jun; 30(3 Suppl 7):25-33. PubMed ID: 12840798
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Lu JF; Eppler SM; Wolf J; Hamilton M; Rakhit A; Bruno R; Lum BL
Clin Pharmacol Ther; 2006 Aug; 80(2):136-45. PubMed ID: 16890575
[TBL] [Abstract][Full Text] [Related]
4. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
6. A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.
Juarez TM; Gill JM; Heng A; Carrillo JA; Wagle N; Nomura N; Nguyen M; Truong J; Dobrawa L; Sivakumar W; Barkhoudarian G; Kelly DF; Kesari S
Neurooncol Adv; 2024; 6(1):vdae049. PubMed ID: 38680990
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines.
Lefebvre C; Pellizzari S; Bhat V; Jurcic K; Litchfield DW; Allan AL
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760847
[TBL] [Abstract][Full Text] [Related]
8. Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core-shell protein nanoparticle.
Gopakumar L; Sreeranganathan M; Chappan S; James S; Gowd GS; Manohar M; Sukumaran A; Unni AKK; Nair SV; Koyakutty M
Drug Deliv Transl Res; 2022 Nov; 12(11):2824-2837. PubMed ID: 35678961
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Painful Palmoplantar Keratoderma Related to Pachyonychia Congenita Using EGFR Inhibitors.
Greco C; Ponsen AC; Leclerc-Mercier S; Schlatter J; Cisternino S; Boucheix C; Bodemer C
Biomedicines; 2022 Apr; 10(4):. PubMed ID: 35453591
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
Mollaei M; Hassan ZM; Khorshidi F; Langroudi L
Transl Oncol; 2021 May; 14(5):101056. PubMed ID: 33684837
[TBL] [Abstract][Full Text] [Related]
11. Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells.
Bouitbir J; Panajatovic MV; Frechard T; Roos NJ; Krähenbühl S
Front Pharmacol; 2020; 11():1106. PubMed ID: 32792947
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
[TBL] [Abstract][Full Text] [Related]
13. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats.
Amor D; Goutal S; Marie S; Caillé F; Bauer M; Langer O; Auvity S; Tournier N
EJNMMI Res; 2018 Aug; 8(1):81. PubMed ID: 30116910
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
Wakelee HA; Gettinger S; Engelman J; Jänne PA; West H; Subramaniam DS; Leach J; Wax M; Yaron Y; Miles DR; Lara PN
Cancer Chemother Pharmacol; 2017 May; 79(5):923-932. PubMed ID: 28352985
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer.
Zhang T; Li Q; Chen S; Luo Y; Fan Y; Xu B
Oncotarget; 2017 May; 8(22):36750-36760. PubMed ID: 27902470
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.
Choi HG; Jeon JY; Im YJ; Kim Y; Song EK; Seo YH; Cho SJ; Kim MG
Clin Drug Investig; 2015 Jan; 35(1):31-43. PubMed ID: 25408262
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Wind S; Schmid M; Erhardt J; Goeldner RG; Stopfer P
Clin Pharmacokinet; 2013 Dec; 52(12):1101-9. PubMed ID: 23813493
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.
Lyseng-Williamson KA
Mol Diagn Ther; 2013 Feb; 17(1):57-62. PubMed ID: 23334845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
